Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...
Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including ...
In a real-world study, In the end, researchers compared 395 ALS patients who'd been given Radicava against 395 matched ...
Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a ...
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...
A new study finds that oral ketamine significantly reduces PTSD symptoms, with 73% of participants seeing a 50% reduction in ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback